Experience

Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 4,791,665 shares of common stock of Natera, Inc. for total gross…

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by InflaRx N.V. of its shares of common stock for up to an aggregate amount of $50…

Davis Polk advised the sole book-running manager in connection with the $215.6 million common stock offering of 6,900,000 shares of common stock of Editas Medicine, Inc. The common…

Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of Insulet Corporation. The offering resulted in approximately $500…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc. of $287.5 million aggregate principal amount of its 2.25%…

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the…

Davis Polk advised the underwriters in connection with Alector, Inc.’s $240 million public offering of 9,602,500 shares of common stock, which includes the 1,252,500 shares offered pursuant…

Davis Polk advised the initial purchasers in connection with an unregistered offering by AbbVie Inc. of $30 billion aggregate principal amount of senior notes, consisting of (i) $750…